Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 205(9):e18–e47. https://doi.org/10.1164/rccm.202202-0399ST

Article  PubMed  PubMed Central  Google Scholar 

Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 378(19):1811–1823. https://doi.org/10.1056/NEJMra1705751

Article  CAS  PubMed  Google Scholar 

Balestro E, Calabrese F, Turato G et al (2016) Immune inflammation and disease progression in idiopathic pulmonary fibrosis. PLoS ONE 11(5):e0154516. https://doi.org/10.1371/journal.pone.0154516

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082. https://doi.org/10.1056/NEJMoa1402584. (Erratum in: N Engl J Med. 2015 Aug 20;373(8):782. 10.1056/NEJMx150012)

Article  CAS  PubMed  Google Scholar 

King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092. https://doi.org/10.1056/NEJMoa1402582. (Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172)

Article  CAS  PubMed  Google Scholar 

Lancaster LH, de Andrade JA, Zibrak JD et al (2017) Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 26(146):170057. https://doi.org/10.1183/16000617.0057-2017

Article  PubMed  PubMed Central  Google Scholar 

Albera C, Costabel U, Fagan EA et al (2016) Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 48(3):843–851. https://doi.org/10.1183/13993003.01966-2015

Article  CAS  PubMed  Google Scholar 

Cocconcelli E, Bernardinello N, Giraudo C et al (2022) Radiological assessment in idiopathic pulmonary fibrosis (IPF) patients according to MUC5B polymorphism. Int J Mol Sci 23(24):15890. https://doi.org/10.3390/ijms232415890

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Li X, Zhang X et al (2024) Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study. BMC Pulm Med 24(1):437. https://doi.org/10.1186/s12890-024-03254-9

Article  PubMed  PubMed Central  Google Scholar 

Bernardinello N, Grisostomi G, Cocconcelli E et al (2022) The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF). Respir Med 191:106686. https://doi.org/10.1016/j.rmed.2021.106686

Article  PubMed  Google Scholar 

Biondini D, Cocconcelli E, Bernardinello N et al (2021) Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. Respir Res 22(1):98. https://doi.org/10.1186/s12931-021-01694-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balestro E, Cocconcelli E, Giraudo C et al (2019) High-resolution CT change over time in patients with idiopathic pulmonary fibrosis on antifibrotic treatment. J Clin Med 8(9):1469. https://doi.org/10.3390/jcm8091469

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bloem AEM, Dolk HM, Wind AE et al (2025) Prognostic value of the 6-min walk test derived attributes in patients with idiopathic pulmonary fibrosis. Respir Med 236:107862. https://doi.org/10.1016/j.rmed.2024.107862

Article  PubMed  Google Scholar 

Lee JH, Jang JH, Jang HJ et al (2023) New prognostic scoring system for mortality in idiopathic pulmonary fibrosis by modifying the gender, age, and physiology model with desaturation during the six-minute walk test. Front Med (Lausanne) 25(10):1052129. https://doi.org/10.3389/fmed.2023.1052129

Article  Google Scholar 

Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GL

Article  PubMed  PubMed Central  Google Scholar 

Raghu G, Remy-Jardin M, Myers JL et al (2018) An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68. https://doi.org/10.1164/rccm.201807-1255ST

Article  PubMed  Google Scholar 

Harrell FE Jr (2015) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, 2nd edn. Springer, New York

Book  Google Scholar 

Hosmer DW, Lemeshow S, Sturdivant RX (2013) Applied logistic regression, 3rd edn. Wiley, New York

Book  Google Scholar 

White H (1980) A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 48(4):817–838

Article  Google Scholar 

Kishaba T, Nagano H, Nei Y et al (2016) Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis 8(6):1112–1120. https://doi.org/10.21037/jtd.2016.03.89

Article  PubMed  PubMed Central  Google Scholar 

Antoniou KM, Hansell DM, Rubens MB et al (2008) Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 177(2):190–194. https://doi.org/10.1164/rccm.200612-1759OC

Article  PubMed  Google Scholar 

Song JW, Hong SB, Lim CM et al (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37(2):356–363. https://doi.org/10.1183/09031936.00159709

Article  CAS  PubMed  Google Scholar 

Yoon HY, Kim H, Bae Y et al (2024) Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study. Respir Res 25(1):191. https://doi.org/10.1186/s12931-024-02819-w

Article  PubMed  PubMed Central  Google Scholar 

Kishaba T, Nagano H, Nei Y et al (2016) Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis 8(6):1112–1120

Article  PubMed  PubMed Central  Google Scholar 

Karampitsakos T, Torrisi S, Antoniou K et al (2021) Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. Respir Res 22(1):140. https://doi.org/10.1186/s12931-021-01725-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kreuter M, Lee JS, Tzouvelekis A et al (2021) Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 204(1):74–81. https://doi.org/10.1164/rccm.202003-0669OC

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biondini D, Balestro E, Lacedonia D et al (2018) Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. Sci Rep 8(1):5961. https://doi.org/10.1038/s41598-018-24303-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amati F, Spagnolo P, Ryerson CJ et al (2023) Walking the path of treatable traits in interstitial lung diseases. Respir Res 24(1):251. https://doi.org/10.1186/s12931-023-02554-8

Article  PubMed  PubMed Central  Google Scholar 

Rice MB, Li W, Schwartz J, Di Q et al (2019) Ambient air pollution exposure and risk and progression of interstitial lung abnormalities: the Framingham Heart Study. Thorax 74(11):1063–1069. https://doi.org/10.1136/thoraxjnl-2018-212877

Article  PubMed  Google Scholar 

Johann